Literature DB >> 8470047

A method to determine the optimal intensity of oral anticoagulant therapy.

F R Rosendaal1, S C Cannegieter, F J van der Meer, E Briët.   

Abstract

Oral anticoagulant therapy has been shown to be effective for several indications. The optimal intensity of anticoagulation for each indication, however, is largely unknown. To determine this optimal intensity, randomised clinical trials are conducted in which two target levels of anticoagulation are compared. This approach is inefficient, since the choice of the target levels will be arbitrary. Moreover, the achieved intensity is not taken into account. We propose a method to determine the optimal achieved intensity of anticoagulation. This method can be applied within a clinical trial as an "efficacy-analysis", but also on data gathered in day-to-day patient care. In this method, INR-specific incidence rates of events, either thromboembolic or hemorrhagic, are calculated. The numerator of the incidence rate is based on data on the INR at the time of the event. The denominator consists of the person-time at each INR value, summed over all patients, and is calculated from all INR measurements of all patients during the follow-up interval. This INR-specific person-time is calculated with the assumption of a linear increase or decrease between two consecutive INR determinations. Since the incidence rates may be substratified on covariates, efficient assessment of the effects of other factors (e.g. age, sex, comedication) by multivariate regression analysis becomes possible. This method allows the determination of the optimal pharmacological effects of anticoagulation, which can form a rational starting point for choosing the target levels in subsequent clinical trials.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470047

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  492 in total

1.  Recommendations for patients undertaking self management of oral anticoagulation.

Authors:  D A Fitzmaurice; S J Machin
Journal:  BMJ       Date:  2001-10-27

2.  Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation.

Authors:  Daniela Poli; Sophie Testa; Emilia Antonucci; Elisa Grifoni; Oriana Paoletti; Gregory Y H Lip
Journal:  Chest       Date:  2011-04-21       Impact factor: 9.410

3.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 4.  A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation.

Authors:  D A Fitzmaurice; P Kesteven; K M Gee; E T Murray; R McManus
Journal:  J Clin Pathol       Date:  2003-01       Impact factor: 3.411

5.  Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration.

Authors:  Adam J Rose; Beth Ann Petrakis; Patricia Callahan; Scott Mambourg; Dimple Patel; Elaine M Hylek; Barbara G Bokhour
Journal:  Health Serv Res       Date:  2012-02-02       Impact factor: 3.402

6.  Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Authors:  Tetz C Lee; Min Qian; Gregory Y H Lip; Marco R Di Tullio; Susan Graham; Douglas L Mann; Koki Nakanishi; John R Teerlink; Ronald S Freudenberger; Ralph L Sacco; J P Mohr; Arthur J Labovitz; Piotr Ponikowski; Dirk J Lok; Conrado Estol; Stefan D Anker; Patrick M Pullicino; Richard Buchsbaum; Bruce Levin; John L P Thompson; Shunichi Homma; Siqin Ye
Journal:  Am J Cardiol       Date:  2018-06-04       Impact factor: 2.778

7.  Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.

Authors:  Carlo Federico Zambon; Vittorio Pengo; Stefania Moz; Dania Bozzato; Paola Fogar; Andrea Padoan; Mario Plebani; Francesca Groppa; Giovanni De Rosa; Roberto Padrini
Journal:  Eur J Clin Pharmacol       Date:  2018-02-02       Impact factor: 2.953

8.  Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Authors:  Aditi Shendre; Gaurav M Parmar; Chrisly Dillon; Timothy Mark Beasley; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2018-02-27       Impact factor: 4.705

9.  A Bayesian dose-individualization method for warfarin.

Authors:  Daniel F B Wright; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

10.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.